Collegium Pharmaceutical to Present Q2 2025 Results Soon

Author: Dylan Bailey Updated: 07-24-2025 08:28 AM

Collegium Pharmaceutical Prepares for Q2 2025 Financial Results

Collegium Pharmaceutical, Inc. (NASDAQ: COLL) is gearing up to share its financial outcomes for the second quarter of 2025. The presentation will occur before the market opens on an anticipated Thursday. Moreover, interested stakeholders can tune in to a live conference call and webcast set to commence at 8:00 a.m. Eastern Time on the same day.

Details of the Conference Call

For those looking to delve deeper into the company's performance, accessing the conference call is straightforward. Participants have the option to dial a dedicated number, with separate lines for U.S. and international attendees. This dialog allows investors and analysts to gain insights into the results and the strategic direction of Collegium following the report.

How to Join the Conference Call

To participate, attendees in the U.S. can call (877) 407-8037, while international participants may connect at (201) 689-8037. When calling, listeners should mention the "Collegium Pharmaceutical Q2 2025 Earnings Call" to ensure they are in the right session. For a broader audience, an audio webcast will be available in the Investors section of the company's official website, providing access to relayed information shortly after the event.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc. has established a strong reputation as a leader in the biopharmaceutical sector, particularly in areas affecting individuals with serious medical conditions. The company focuses on creating and marketing responsible pain management medications. A notable addition to their portfolio is Jornay PM, a treatment for ADHD which signifies their expansion into neuropsychiatry.

Strategic Growth Initiatives

The strategic roadmap for Collegium involves a concerted effort to expand its commercial offerings. Jornay PM serves as a primary growth driver while the company aims to wisely invest its capital in various prospective ventures. With a commitment to enhancing the quality of life for patients, Collegium continuously seeks innovative solutions to meet their needs.

Staying Informed with Collegium

For individuals keen on understanding Collegium's trajectory and future activities, the company's website remains a resourceful hub. Investors and interested parties can find robust updates from financial reports to company news. Collegium encourages all stakeholders to stay engaged through regular visits to its digital platforms.

Contact Information

The investor relations team at Collegium is always ready to assist. For inquiries regarding investor relations, interested individuals can reach out via email to Ian Karp, the Head of Investor Relations, or Danielle Jesse, the Director of Investor Relations. Their commitment to transparency ensures that stakeholders have the information they require.

Frequently Asked Questions

What financial results are being reported by Collegium?

Collegium will report its financial outcomes for the second quarter of 2025.

When will the conference call take place?

The conference call is scheduled for 8:00 a.m. ET on the day the financial results are announced.

How can I participate in the conference call?

You can call (877) 407-8037 for U.S. listeners or (201) 689-8037 for international callers.

What is Jornay PM?

Jornay PM is Collegium's ADHD treatment that recently expanded its portfolio.

Who can I contact for investor relations inquiries?

You can email Ian Karp or Danielle Jesse for inquiries related to investor relations at Collegium.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.